Clinical Trials
273
Trial Phases
3 Phases
Drug Approvals
21
Drug Approvals
Avalglucosidase Alfa for Injection
- Product Name
- 耐而赞
- Approval Number
- 国药准字SJ20230015
- Approval Date
- Sep 28, 2023
Cross-linked Sodium Hyaluronate Injection
- Product Name
- 欣维可
- Approval Number
- 国药准字HJ20160580
- Approval Date
- Jul 29, 2021
Cross-linked Sodium Hyaluronate Injection
- Product Name
- 欣维可
- Approval Number
- 国药准字HJ20160464
- Approval Date
- Jul 29, 2021
Clinical Trials
Distribution across different clinical trial phases (241 trials with phase data)• Click on a phase to view related trials
News
Ultragenyx Appoints Eric Olson as Chief Business Officer to Lead Rare Disease Pipeline Expansion
Ultragenyx Pharmaceutical appointed Eric Olson as Chief Business Officer and Executive Vice President effective September 22, 2025, following Thomas Kassberg's planned retirement after 14 years with the company.
BioCryst Names Charlie Gayer as New CEO Following Jon Stonehouse's Retirement Announcement
BioCryst Pharmaceuticals announced that CEO Jon Stonehouse will retire on December 31, 2025, with current Chief Commercial Officer Charlie Gayer set to succeed him as president in August and CEO in January 2026.
Crescent Biopharma Appoints Jan Pinkas as Chief Scientific Officer to Advance Oncology Pipeline
Crescent Biopharma has appointed Jan Pinkas, Ph.D., as chief scientific officer, bringing over two decades of oncology drug development experience including expertise in antibody-drug conjugates.